#USA #Helix #San Mateo, California #Mawi DNA #Genomic Collection

Helix Partners with Mawi DNA Technologies to Enhance Non-Invasive Genomic Sample Collection

In a significant move aimed at revolutionizing genomic research, Helix, a leading player in the enterprise genomics sector, has announced its partnership with Mawi DNA Technologies. This collaboration is set to broaden access to non-invasive DNA sampling techniques, a crucial advancement for population genomics, particularly in making genomic data collection more efficient and inclusive.

Enhancing Participation in Genomic Studies

The partnership's primary goal is to facilitate easier access to genomic information from a wider range of individuals. With the introduction of buccal swab technology, participants can now provide DNA samples by swabbing cells from the inside of their cheeks. This method is not only quick and painless but also designed to effectively enhance the collection process while minimizing errors, resampling, and overall operational costs.

Helix recognizes that a single approach to DNA collection does not fit all. While traditional saliva-based collection methods are prevalent, they may not be suitable for everyone—especially infants, elderly patients, or individuals with medical conditions affecting saliva production. By incorporating buccal swabs into their existing methods, Helix expands its toolkit, thus ensuring more consistent and reliable sample collection across diverse populations.

Flexibility and Quality in Genomic Data

James Lu, CEO of Helix, emphasized the importance of this multimodal collection strategy. He stated, “By adding buccal swab collection to our existing blood and saliva options, we provide our partners with greater flexibility to design appropriate programs tailored to their specific demographics.” This approach not only heightens participation rates but also guarantees high-quality genomic data, driving impactful clinical and research insights.

The incorporation of Mawi's technology promises to bolster Helix’s existing genomic sequencing endeavors, enhancing collection capabilities and contributing to more accurate data generation across various cohorts. This development speaks to the growing recognition among health systems and life sciences entities that diverse pathways must be established to collect high-quality genomic data.

A Shared Vision for Global Sample Diversity

Dr. Bassam El-Fahmawi, CEO and Chief Technical Officer of Mawi DNA, expressed enthusiasm regarding the partnership. He stated, “We are thrilled that Helix has selected Mawi's sample collection technology as a crucial part of their initiative to understand population genomics on a global scale.” This collaboration aligns with Mawi’s commitment to making genomic data collection accessible for all individuals, irrelevant of their age or geographical context. Global sample diversity is indispensable for obtaining a detailed understanding of genetic diseases and their implications on health across various communities.

About Helix and Mawi DNA Technologies

Helix is recognized as a premier enterprise genomics platform, empowering health organizations to leverage genomics for substantial strategic advantages. Their Helix Research Network is North America’s largest precision health network, planting the seeds for genomic discoveries that translate into clinical applications.

Conversely, Mawi DNA Technologies, established in 2013, has pioneered the iSWAB technology—an advanced system for biosample collection. They specialize in maintaining sample integrity at room temperature from any location, thereby promoting true global sample diversity. Their flagship product, iSWAB-DNA, is unique in its ability to deliver high-quality DNA samples with significantly low bacterial DNA contamination.

The combination of these two innovative forces in genomics ushers in a new era of accessible and efficient genomic data collection methods, promising profound impacts on health research and patient care across populations. As they continue to evolve, the collaboration stands as a testament to the potential of combining cutting-edge technology and forward-thinking research initiatives.